Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Business Wire•23/07/2026•08:01 ET
0
Whiz Insights
Get started
Create a free account to read the full story.